SIGN UP

Sio Gene Therapies founder Vivek Ramaswamy (JPM20)

April 28, 2022 03:16 AM EDTUpdated 09:02 AM

Axovant-turned-Sio ditches two remaining programs, lays off most employees and will seek a buyer

Kyle LaHucik

Senior Reporter

A year and a half ago, Sio Gene Therapies attempted to steer into a new history, with then-CEO Pavan Cheruvu telling Endpoints News it was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Trump names Johns Hopkins researcher Marty Makary to lead the FDA

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

sponsored

Are programs with compounded GLP-1s safe for your population?